Loading…
Loading…
As of 20 Nov 2026: COHANCE ₹462.30 (m-cap ₹17,706 Cr, P/E 372.8) vs Rubicon Research ₹1,718.70 (m-cap ₹28,530 Cr, P/E 87.4). Compare ROE, ROCE, growth, debt, dividends and 1-year returns.
As of · NSE prices; ratios from company filings
| Metric | COHANCE | Rubicon Research |
|---|---|---|
| Share price | ₹462.30 | ₹1,718.70 |
| Day change | +0.62% | −0.21% |
| Market cap | ₹17,706 Cr | ₹28,530 Cr |
| P/EPrice ÷ trailing 12-month earnings per share; blank for a loss. | 372.8 | 87.4 |
| P/BPrice ÷ book value per share. | 4.5 | 20.1 |
| ROEReturn on equity. | 4.9% | 27.0% |
| ROCEReturn on capital employed. | 6.0% | 28.0% |
| Sales growth (3Y CAGR) | 19.2% | 64.6% |
| Profit growth (3Y CAGR) | -22.7% | 155.0% |
| Debt to equity | 0.11 | 0.35 |
| Dividend yield | 0.00% | 0.09% |
| 1-year price return | −20.6% | +146.9% |
| Promoter holding | 57.5% | 51.2% |
| Industry | Pharmaceuticals | Pharmaceuticals |
Open in the compare tool for price charts from one month to five years, scorecards and more companies.
Each line states which company has the higher or lower figure; none of them is a recommendation.
Rubicon Research Ltd is larger, with a market cap of ₹28,530 Cr against ₹17,706 Cr for Cohance Lifesciences Ltd as of 20 Nov 2026 — about 1.6 times the size.
Rubicon Research Ltd trades at a P/E of 87.4 against 372.8 for Cohance Lifesciences Ltd as of 20 Nov 2026. A lower P/E alone does not make a share cheaper in value terms: growth, return on capital and debt differ between companies.
Jivani Markets does not give buy, sell or hold recommendations and is not a SEBI-registered investment adviser or research analyst. The table on this page lays out the facts side by side — price, valuation, returns on capital, growth, debt, dividends and promoter holding — so you can weigh them against your own goals, or with a SEBI-registered adviser.
Prices refresh every few minutes during market hours and ratios update when the companies report results. Each number is the same one shown on the two stock pages.